Cartalax

Cartalax is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family, researched for cartilage-targeted bioregulation, joint tissue support, and connective tissue function. It is one of the synthesized Khavinson compounds with a defined three-amino-acid sequence. Cartalax is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.

What is Cartalax and how does the cartilage-targeted bioregulatory mechanism work?

Cartalax is a synthetic Ala-Glu-Asp tripeptide proposed to enter chondrocyte and connective-tissue cell nuclei and modulate gene expression in pathways related to cartilage matrix production, chondrocyte maintenance, and joint tissue homeostasis. Within the Khavinson framework, Cartalax is positioned as the cartilage-targeted bioregulator complement to organ-specific peptides like Cardiogen (cardiac) and Vesugen (vascular). Cartilage and connective tissue are Cartalax's designated target within the Khavinson framework; the verifiable preclinical record, however, is limited to in-vitro cell-culture studies of short peptides (renal, dermal-fibroblast, and stem-cell renewal models) rather than cartilage-specific efficacy work. For the framework itself, see the science of Khavinson bioregulators.

Evidence level: preclinical (cell culture, limited rodent); Khavinson-group research; independent replication limited

What does the research show for Cartalax?

Independent, chondrocyte-specific efficacy data has not been published; the available Khavinson-group and collaborator studies are in-vitro cell-culture experiments on cell renewal and gene expression, and no human trial has been conducted. Human clinical research at FDA-grade Phase 2/3 standards has not been conducted. No human clinical trial of Cartalax — controlled or observational — has been published as of August 2026; the verifiable literature is a small set of in-vitro cell-culture studies of short peptides. Claims of clinical use in osteoarthritis or joint recovery are not supported by a citable source.

Evidence level: preclinical (cell culture); Khavinson-group research; FDA-grade Phase 2/3 not conducted

How does Cartalax compare to other Khavinson peptide bioregulators?

Cartalax targets connective tissue (cartilage), distinguishing it within the Khavinson cluster where most compounds target single-organ systems. Its sequence and structure follow the standard Khavinson tripeptide pattern.

What are the documented side effects of Cartalax?

Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. The Khavinson bioregulator class as a whole has a favorable safety profile in available data. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards.

Evidence level: preclinical safety; human long-term unestablished

What is the regulatory status of Cartalax?

Cartalax is not approved by the FDA, EMA, or any major Western regulator as of August 2026. Cartalax is not on the FDA's active Section 503A/503B Category-2 bulk-substances list and was not among the peptides addressed in the FDA's April 2026 Category-2 actions or the July 2026 Pharmacy Compounding Advisory Committee meeting — no U.S. compounding pathway applies to it. It is used in Russian clinical and research contexts as part of Khavinson-framework protocols. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Source: FDA 503A bulk drug substances (Category 1/2) page

Why does Cartalax vendor verification matter?

Cartalax shares structural similarity with several other Khavinson tripeptides — Ala-Glu-Asp varies from other tripeptides in the cluster by single amino acid substitutions — making mass spectrometry identity confirmation important to verify the correct sequence. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Cartalax vendors?

Peptigrity collects independent third-party Certificates of Analysis for Cartalax from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does Cartalax do?

Cartalax is proposed to act on cartilage and connective tissue through epigenetic gene-expression modulation, with preclinical research focused on chondrocyte function, collagen synthesis, and cartilage matrix production. Human Phase 2/3 efficacy is not established at Western clinical standards.

Is Cartalax legal to purchase?

Cartalax is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Cartalax be FDA-approved?

No active FDA approval pathway exists for Cartalax as of August 2026.

How can I verify a Cartalax vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Mass spec is essential because Cartalax shares amino acid composition with other Khavinson tripeptides. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Cartalax dose?

No. Cartalax is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

How does Cartalax compare to BPC-157 for joint research?

Different mechanism families — Cartalax operates through proposed epigenetic gene-expression modulation in connective tissue; BPC-157 is a 15-amino-acid peptide proposed to act through angiogenesis, growth-factor signaling, and tissue-repair pathways. They are not interchangeable; BPC-157 has substantially more independent research support, while Cartalax has Khavinson-framework theoretical positioning specific to cartilage.

This section is for educational and informational purposes only and does not constitute medical advice. Cartalax is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.